HKSE:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-07 17:52 UTC

Last close

n/aHKD

Market data

We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.

82.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed
- Computed from the filing for 2025
21.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
12.6%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
20.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.27Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.12 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.96x

-0.59x

-1.22x

1.31x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.96x
Its own average over 6 years, 703.0M.
Profit-0.59x
Its own average over 6 years, -292.0M.
Free cash flow-1.22x
Its own average over 6 years, -231.1M.
Debt1.31x
Its own average over 6 years, 444.6M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at -1.22 times.

It reports in CNY and trades in HKD. Nothing on this page is converted between the two.

The filed years, as a table

Each line is 100 at 2020-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2020-12-31	100.0	100.0
2021-12-31	139.8	100.0
2022-12-31	210.6	99.0
2023-12-31	282.8	100.4
2024-12-31	386.7	100.3
2025-12-31	543.8	100.9

How sales was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

How shares in issue was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

Figures behind the shape

Growth

40.3%

faster is higher, placed against 4,950 companies as of 2026-11-06

Five-year revenue growth rate40.3%
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed
One-year change in net income416.4%
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed

Returns on capital

21.5%

higher is higher, placed against 5,089 companies as of 2026-11-06

Return on invested capital21.5%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity8.0%
Net Income / Shareholders' Equity x 100
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets4.7%
Net Income / Total Assets x 100
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025

Margins

75.8%

wider is higher, placed against 3,412 companies as of 2026-11-06

Gross margin75.8%
Gross Profit / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin20.2%
Operating Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin12.6%
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin20.5%
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025

Price

82.2x

cheaper is higher, placed against 4,362 companies as of 2026-11-06

Price to earnings82.2x
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed
- Computed from the filing for 2025
Price to book6.5x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA31.4x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio10.3x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025

Safety

0.27

safer is higher, placed against 3,227 companies as of 2026-11-06

Debt to equity0.27
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio2.31
Current Assets / Current Liabilities
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage3.9x
Operating Income / Interest Expense
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score5.91
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Taken on
2026-11-07
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
HKD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.